Phospho-FGFR1 is difficult to detect by immunoblotting in FGFR-amplified cancer cells because there is currently no reliable anti-phospho-FGFR1 antibody [30, 32]; therefore, we examined classic FGFR1 downstream signaling as a surrogate for FGFR1 activation in FGFR1-amplified NCI-H1581 cells. The gene discussed is FGFR1; the disease is cancer.